ARTICLE | Clinical News

BioCanCell reports Phase I/IIa data for BC-819 in bladder cancer

February 16, 2018 5:28 PM UTC

BioCanCell Ltd. (Tel Aviv:BICL) reported final data from a Phase I/IIa trial in 38 patients with resected, early stage non-muscle invasive bladder cancer (NMIBC) showing that BC-819 plus bacillus Calmette-Guérin (BCG) led to a 24-month recurrence-free survival rate of 54% and a 24-month progression-free survival (PFS) rate of 76%. Overall median time to recurrence was not reached at a median follow-up of 18 months. BC-819 was well tolerated with no treatment-related serious adverse events reported. Data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco.

The open-label, Israeli trial evaluated three intravesical combination induction schedules of BC-819 and BCG. The trial's primary endpoint was safety and the secondary endpoint was rate of recurrence...